Effects of intranasal administration of the peptide antagonist of type I vaniloid receptor (TRPV1) in the rodent central nervous system

Intranasal administration of the polypeptide APHC3, an antagonist of the TRPV1 receptor, had acute anxiolytic and antidepressant effects, as well as an ability to modify the microglial response to proinflammatory stress and cytokine profile of the hippocampus. However, the acute antidepressant effec...

Full description

Saved in:
Bibliographic Details
Published in:Doklady. Biological sciences 2016-09, Vol.470 (1), p.234-236
Main Authors: Tishkina, A. O., Mart’yanova, E. K., Logashina, Yu. A., Andreev, Ya. A., Khaibullina, S. F., Martynova, E. V., Rizvanov, A. A., Gulyaeva, N. V., Grishin, E. V.
Format: Article
Language:English
Subjects:
Administration, Intranasal
Analgesics - administration & dosage
Animals
Anti-Inflammatory Agents - administration & dosage
Antidepressive Agents - administration & dosage
Biomedical and Life Sciences
Cnidarian Venoms - administration & dosage
Cytokines - metabolism
Depression - diagnosis
Depression - drug therapy
Depression - physiopathology
Dose-Response Relationship, Drug
Evolutionary Biology
General Biology
Hippocampus - drug effects
Hippocampus - physiology
Life Sciences
Male
Peptides - administration & dosage
Plant Sciences
Rats
Rats, Wistar
Treatment Outcome
TRPV Cation Channels - antagonists & inhibitors
TRPV Cation Channels - metabolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Intranasal administration of the polypeptide APHC3, an antagonist of the TRPV1 receptor, had acute anxiolytic and antidepressant effects, as well as an ability to modify the microglial response to proinflammatory stress and cytokine profile of the hippocampus. However, the acute antidepressant effect of the polypeptide was not related to the attenuation of neuroiflammation and probably had a different mechanism. The use of intranasal administration of the APHC3 peptide as a therapeutic approach aimed at decreasing depression symptoms needs additional studies in order to find the mechanism of action of this polypeptide in the central nervous system (CNS).
ISSN:0012-4966
1608-3105
DOI:10.1134/S0012496616050082